Yang et al. (2019) enrolled for a phase I study (US NIH Clinical#: NCT03825731) 17 patients with relapsed/refractory B-ALL including 4 pts previously treated with CD19 CAR-T cells. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.